Celltrion, Inc. & Celltrion Healthcare Co., Ltd. Announce Shareholders Approval of Merger

Contributed by: Business Wire

Logo

Images

Zymfentra® (Photo: Celltrion)

Business Wire embedded0

Tags

Research

Finance

Professional Services

Biotechnology

Health

Pharmaceutical

General Health

Other Professional Services

Science

Shareholders Approval of Merger Agreement

More Like This

Celltrion Announces the Acquisition of iQone Healthcare Switzerland, Further Building Its Expertise and Foothold in Europe

Celltrio Secures $15 Million Financial Investment to Accelerate Global Expansion in Cell Culturing and Cell & Gene Therapy Automation

Celltrion opens new UK headquarters in Uxbridge, UK

Celltrion opens new UK headquarters in Uxbridge, UK

Viromed Medical AG Plans to Acquire All Shares of ActivCell Group AG by Way of a Capital Increase Against Contribution in Kind with Exclusion of Subscription Rights

CBC-Backed Hasten Biopharmaceutical Announces Acquisition of 14 Celltrion Legacy Products

Celltrion receives European Commission approval of Omlyclo® (CT-P39), the first and only omalizumab biosimilar approved in Europe

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti-CD40 mAb) Phase I Trial at ESMO 2023